Latest ACR News
-
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.Read Article
Dr Irwin Lim _connectedcare
5 years 1 month ago
Ixekizumab in nrAXSpa
Outcomes met. Another positive trial
#ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ
Dr Irwin Lim _connectedcare
5 years 1 month ago
Ixekizumab in nrAXSpa: COAST-X
switch at wk16 for 52wk study
IXE 2wkly vs 4wkly vs PBO
303pts
#ACR19 @rheumnow Abst2729
Dr. Rachel Tate uptoTate
5 years 1 month ago
@KDAO2011 teaching us about SLE @RheumNow #ACR19 it’s almost your last chance to swing by the rheumnow booth! https://t.co/pBdFAwGXtm
Dr. John Cush RheumNow
5 years 1 month ago
Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH
Jonathan Hausmann MD hausmannMD
5 years 1 month ago
How should VECTRA be used, if at all?
-Bathon I don't use VECTRA routinely, it's as good as your physical exam.
-Bykerk: I've yet to find a good reason to use it.
-Emery ::no comment::
-Mikuls: I don't think there's a place in my clinic to use it.
#ACR19 @RheumNow
David Liew drdavidliew
5 years 1 month ago
@cappelliMD @Richter_MD @LCalabreseDO @CCalabreseDO @lexmeara @UmaThanaMD Nice work @Richter_MD - such an important phenomenon. It’s always something nice to tell my melanoma irAE patients: your arthritis might be nasty, but at least there’s a substantive upside!
#ACR19 ABST2137 @RheumNow
(sorry to miss you in person!) https://t.co/x1T9n9eekG
Jonathan Hausmann MD hausmannMD
5 years 1 month ago
38yo F with seroneg RA on 3x therapy with synovitis. What tx do you choose?
-Bathon: Confirm dx, use biologic, avoid ritux
-Bykerk: Ask about JIA, use TNF, JAK, IL-6
-Emery: Not ritux. Use steroids, consider TNFi, urgent tx is not needed
-Mikuls: Agree with above
#ACR19 @RheumNow
Mike Putman EBRheum
5 years 1 month ago
@RheumNow Should note this was not the first JAKi in this space; similar trial using tofacitinib in 2017 https://t.co/NrEul0wLp9
Mike Putman EBRheum
5 years 1 month ago
#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa
Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.
Good safety profile but too small a trial to assess properly
Overall an encouraging result, JAKi impacting yet another disease!
@RheumNow https://t.co/GtB9wHuoNp
Dr Irwin Lim _connectedcare
5 years 1 month ago
Upadacitinib in AS
Nice to the rapid response
#ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY
Jonathan Hausmann MD hausmannMD
5 years 1 month ago
What's your option for RA patients with MTX failure?
-Bathon: Triple therapy vs. biologic (etanercept or adalimumab)
-Bykerk: Maximize MTX to 25mg SQ
-Emery: Adalimumab is our cheapest and most effective therapy
-Mikuls: Usually TNFi, typically etanercept
#ACR19 @RheumNow
Maeve Gamble MaeveGamble
5 years 1 month ago
Do you hold MTX in men who want to conceive? #ACR19 @RheumNow
Dr Irwin Lim _connectedcare
5 years 1 month ago
Upadacitinib in AS
And here’s the Safety Slide
#ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N
Dr. John Cush RheumNow
5 years 1 month ago
Looking forward to this PsA panel talk #ACR2019 https://t.co/pCMaqQCMsJ
Maeve Gamble MaeveGamble
5 years 1 month ago
For new diagnosis of RA: How often do you bridge with prednisone?
#ACR19 @RheumNow